Additionally, AAbs such as antinuclear, anti-thyroglobulin, anti-thyroid peroxidase, p53, BRCA2, HUD, and TRIM21 have been identified as predictors of PFS and overall survival (OS) in NSCLC undergoing ICIs therapy (20, 21, 22, 23). Here, BRCA2 is linked to non-small cell lung carcinoma.